A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.

doi:10.1158/1078-0432.CCR-11-0227

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2011

Sung Wen-Wei, Wang Yao-Chen, Cheng Ya-Wen, Lee Ming-Ching, Yeh Kun-Tu, Wang Lee, Wang John, Chen Chih-Yi, Lee Huei

Abstract excerpt

PURPOSE: Fas ligand (FasL) -844T/C polymorphism (rs763110) has a demonstrated association with lung cancer risk. FasL -844CC with higher FasL expression has been suggested to contribute to tumor progression via immune escape. However, the impact of FasL -844T/C polymorphism on the clinical outcome of non-small cell lung cancer (NSCLC) remains to be identified. EXPERIMENTAL DESIGN: A total of 385 adjacent normal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fas Ligand Protein

Share to Kaplan-Meier Estimate

Share to Neoplasm Invasiveness

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to T-Lymphocytes

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 21807637
DOI: 10.1158/1078-0432.CCR-11-0227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.PMID 21807637Read ↗

Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.Semantic proximity Read ↗

FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.Semantic proximity Read ↗

Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.Semantic proximity Read ↗

The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.Semantic proximity Read ↗

FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.Semantic proximity Read ↗

FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population.Semantic proximity Read ↗

Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.Semantic proximity Read ↗

Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy.Semantic proximity Read ↗

Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer.Semantic proximity Read ↗

Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis.Semantic proximity Read ↗

Fas -670 A/G polymorphism predicts prognosis of hepatocellular carcinoma after curative resection in Chinese Han population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.